VIAC

ViacomCBS Inc.

29.58
USD
-17.81%
29.58
USD
-17.81%
27.84 101.97
52 weeks
52 weeks

Mkt Cap 17.95B

Shares Out 606.71M

Send me real-time posts from this site at my email

Amneal Pharma Announces FDA Approval For Its Biosimilar Referencing Neulasta

(RTTNews) - Amneal Pharmaceuticals, Inc. (AMRX) announced the FDA has approved the company's Biologics License Application for pegfilgrastim-pbbk, a biosimilar referencing Neulasta. The product will be marketed under the name FYLNETRA. FYLNETRA was developed in collaboration with Kashiv Biosciences. It is used to treat neutropenia. The company noted that this marks the third biosimilar approval Amneal received this year for products used in oncology. Amneal expects to launch these three products over the second half of 2022. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue